What are the indications, recommended dosing, contraindications, and counseling points for mefenamic acid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mefenamic Acid: Clinical Overview

Indications

Mefenamic acid is FDA-approved for relief of mild to moderate pain in patients ≥14 years of age (maximum 7 days) and for treatment of primary dysmenorrhea 1.

Beyond these core indications, the drug appears in multiple ESMO cancer pain guidelines as a WHO Step I analgesic option for mild pain management 2, 3, 4, 5, 4, 6, 4. Additional evidence supports its use for:

  • Menorrhagia: Demonstrated 86% control rate versus 20% with placebo, reducing bleeding days from 9.7 to 4.1 days 7
  • Premenstrual syndrome: Significantly improved tension, irritability, depression, pain and headache (though not breast symptoms) 8
  • Acute postoperative pain: NNT of 4.0 for 50% pain relief over 6 hours 9
  • Bleeding irregularities with Cu-IUD: Effective for short-term treatment (5-7 days) of heavy or prolonged menstrual bleeding 10
  • Bleeding with contraceptive implants: 500 mg three times daily for 5 days significantly improved bleeding cessation 10

Emerging pediatric data suggests efficacy for febrile illness in children ≥6 months, though long-term safety data remain limited 11, 12.

Recommended Dosing

For acute pain (adults and adolescents ≥14 years):

  • Initial dose: 500 mg
  • Maintenance: 250 mg every 6 hours as needed
  • Maximum duration: 7 days 1

For primary dysmenorrhea:

  • Initial dose: 500 mg at onset of bleeding/symptoms
  • Maintenance: 250 mg every 6 hours
  • Duration: Typically 2-3 days 1

For menorrhagia:

  • 500 mg every 8 hours starting day 1 of cycle for 5 days or until cessation of menses 7

For Cu-IUD or implant-related bleeding:

  • Short-term treatment: 5-7 days during bleeding episodes 10

Pediatric dosing (based on emerging evidence):

  • 5 mg/kg three times daily for up to 3 days 12
  • Note: FDA approval only for ≥14 years; pediatric use requires careful consideration 11

Maximum daily dose across all indications: 2000 mg (4 × 500 mg) 2, 3, 4, 5, 4, 6, 4

Time to onset: Approximately 30 minutes 2, 3, 4, 5, 4, 6, 4

Contraindications and Cautions

Primary concerns are gastrointestinal and renal toxicity 2, 3, 4, 5, 4, 6, 4. The FDA label emphasizes using the lowest effective dose for the shortest duration to minimize GI bleeding, ulceration, and perforation risk 1.

Specific contraindications include:

  • Active GI bleeding or obstruction
  • Severe renal or hepatic impairment
  • Aspirin/NSAID-induced asthma
  • Active thromboembolic disease (if considering tranexamic acid as alternative) 10

Critical safety considerations:

  • Seizure risk: Mefenamic acid uniquely carries higher CNS toxicity risk among NSAIDs, with seizures reported even at therapeutic doses (60 mg/kg) and serum levels >25 µg/mL 13
  • Acute kidney injury: Can develop 2-3 days post-ingestion, even without initial renal dysfunction 13
  • Duration limits: FDA restricts pain treatment to 7 days maximum; dysmenorrhea treatment typically 2-3 days 1
  • Gastric protection: Recommended when used over prolonged periods 3
  • Bleeding risk: Monitor patients at risk; avoid in those with bleeding disorders 3

Counseling Points

Inform patients to:

  1. Take with food to minimize GI upset

  2. Stop immediately and seek care if experiencing:

    • Black/tarry stools or blood in stool
    • Severe abdominal pain
    • Seizures or altered mental status
    • Decreased urine output or swelling
    • Allergic reactions (rash, difficulty breathing)
  3. Adhere to duration limits: Maximum 7 days for pain, 2-3 days for dysmenorrhea 1

  4. Avoid concurrent NSAIDs to prevent additive toxicity

  5. Report pre-existing conditions: Particularly renal disease, liver disease, cardiovascular disease, or history of GI ulcers

  6. Pregnancy/lactation: Discuss risks; generally avoid in third trimester

  7. Timing for dysmenorrhea: Start at onset of bleeding/symptoms for optimal efficacy 1

  8. Expected effects: Pain relief typically within 30 minutes; sustained normothermia in fever cases averages 62 hours 12

Clinical Pearls

  • Unique pharmacology: Mefenamic acid offers preferential COX-2 inhibition, EP receptor blockade, and NLRP3 inflammasome inhibition, distinguishing it from other NSAIDs 11
  • Superior antipyretic effect: Limited data suggest potential advantages over paracetamol and ibuprofen for fever 11
  • Menorrhagia efficacy: Among the most effective NSAIDs for this indication with robust evidence 7
  • Delayed renal toxicity: AKI may not manifest until day 3 post-ingestion; maintain vigilance 13
  • Not for chronic use: Unlike other NSAIDs, mefenamic acid is specifically limited to short-term therapy due to safety profile

References

Research

Management of cyclical menorrhagia with prostaglandin synthetase inhibitor.

Asia-Oceania journal of obstetrics and gynaecology, 1990

Research

The treatment of premenstrual symptoms with mefenamic acid.

British journal of obstetrics and gynaecology, 1980

Research

Single dose oral mefenamic acid for acute postoperative pain in adults.

The Cochrane database of systematic reviews, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.